Advertisements

Sensibit D NF

Quick links to important sections

Sensibit D NF

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Sensibit D NF

Property Description
Active Ingredients Acetaminophen, Loratadine, Phenylephrine Hydrochloride
Form Oral tablet, caplet, or capsule
Pharmacological Class Upper respiratory combination product
Common Use Symptomatic relief of cold, flu, and allergy-related discomfort
Origin Synthetic

What is Sensibit D NF and What Pharmacological Class Does It Belong To?

Sensibit D NF is a synthetic, oral, fixed-dose combination (FDC) medicine classified pharmacologically as an upper respiratory combination product. This preparation is designed to simultaneously deliver multiple therapeutic actions against the symptoms of common illnesses. The FDC approach integrates three distinct active substances into a single, standardized unit, a structure recognized for multi-symptom management when cold and allergic symptoms coexist.

The Composition of Sensibit D NF: Three Active Ingredients

The medication contains three core active ingredients: Acetaminophen, Loratadine, and Phenylephrine Hydrochloride. Each ingredient represents a different pharmacological class. Acetaminophen functions as an analgesic and antipyretic (pain and fever reducer); Loratadine is a non-sedating second-generation antihistamine; and Phenylephrine Hydrochloride acts as a sympathomimetic nasal decongestant. Loratadine targets histamine receptors, a mechanism that helps prevent allergy-related reactions without typically causing the drowsiness often associated with older antihistamines. This tripartite composition provides a broad therapeutic spectrum that addresses a wide range of symptomatic discomfort in a single oral form.

General Purpose: Multi-Symptom Symptomatic Relief

The general purpose of Sensibit D NF is to provide comprehensive multi-symptom symptomatic relief for upper respiratory conditions. A typical scenario for its use involves managing the combination of fever, headache, and significant nasal congestion common during a cold or a flare-up of allergic rhinitis. The medicine is designed so that the convergence of its three mechanisms of action addresses both systemic discomfort—such as body aches and elevated temperature—and localized irritations—like congestion and allergic responses. By combining these therapeutic actions, the medication offers integrated support, aimed at improving overall functional comfort during the course of a respiratory ailment.

Advertisements

What side effects are possible with Sensibit D NF?

The possible adverse effects and safety characteristics of this combination medicine are systematically classified in official regulatory documents according to the body system affected and the reported frequency of occurrence.

Officially Documented Adverse Reactions by System

Adverse reactions are formally grouped into System-Organ Classes. Effects that are commonly documented tend to involve the Nervous System (e.g., headache, drowsiness, insomnia, nervousness) and the Gastrointestinal System (e.g., dry mouth, nausea).

Due to the sympathomimetic component, effects on the Cardiovascular System, such as palpitations and increased blood pressure, are officially documented as uncommon adverse reactions. Furthermore, effects on the Hepatobiliary System, including hepatic dysfunction and elevated liver enzymes, are a documented safety risk primarily associated with the Acetaminophen component.

Serious Adverse Reactions and Safety Constraints

Regulatory labeling specifies rare but clinically significant adverse reactions, which include Severe Hepatotoxicity and Hepatic Failure, particularly linked to high cumulative Acetaminophen exposure. Rare, severe skin reactions, such as Stevens-Johnson Syndrome (SJS), are also documented safety concerns. Additionally, the regulatory profile includes specific, high-level safety constraints.

The product is formally contraindicated in individuals with severe, active hepatic impairment. A critical constraint also exists regarding co-administration with Monoamine Oxidase Inhibitors (MAOIs), where the use is associated with a serious safety risk of a severe hypertensive crisis, as documented in government prescribing information. Safety considerations are also noted for older adults due to potential sensitivity to cardiovascular effects and for patients with renal impairment.

Advertisements

Overdose and Emergency Response

Sensibit D NF Overdose and When to Seek Help

Overdose Scope

Documented overdose presentations primarily involve hepatic and cardiovascular/CNS manifestations. Early symptoms of potential overdose may include non-specific signs such as nausea, vomiting, loss of appetite, sweating, and abdominal pain. Later, delayed and severe manifestations of hepatic injury, such as jaundice (yellowing of skin/eyes), dark urine, and pain in the upper right abdomen, may present. Cardiovascular and central nervous system (CNS) effects can include tachycardia (fast heart rate), hypertensive crisis (dangerously high blood pressure), tremor, and seizures or somnolence.

Emergency Response Statements

Seek immediate medical attention or contact a Poison Help line right away. Prompt medical attention is critically required for any suspected overdose, even if the patient has no initial signs or symptoms, as the most severe effects can be delayed. Treatment protocols include general symptomatic and supportive measures. The substance N-acetylcysteine is the specified antidote for the Acetaminophen component overdose, and its efficacy is highest when administered within the critical early hours after ingestion.

Connection to the Overall Overdose Profile

Regulatory documents define this overdose profile by emphasizing the potential for life-threatening acute liver failure from the Acetaminophen component, which mandates the urgent help-seeking requirement. The profile is further structured by the documented acute risks of severe cardiovascular and neurological symptoms from the decongestant and antihistamine components, necessitating specialized monitoring.

Advertisements

Therapeutic Uses of Sensibit D NF

This type of combination medicine is used for the symptomatic management of common illnesses and related conditions.

This medication is commonly used across conditions presenting with acute episodes where multiple forms of discomfort, such as pain, fever, nasal congestion, and allergic responses, may present concurrently. This often occurs during episodes of the common cold, flu, or seasonal allergic rhinitis.

Sensibit D NF is relevant for easing symptoms related to physical discomfort, including headache and body aches, alongside the elevated temperature. It helps address symptom clusters that may become intense or disruptive, such as nasal congestion, sneezing, and runny nose.

“It provides support that helps ease the overall symptom burden when multiple symptoms cluster together.”

The primary therapeutic benefit is that it helps patients cope more steadily with symptom fluctuations during challenging symptomatic phases.

Quick Fact: Relief for Multi-Symptom Discomfort

The combination is applied across domains where additional symptomatic support is needed, targeting pain, fever, nasal blockage, and allergic response manifestations. This assists with maintaining a sense of stability during symptomatic periods.

Regulatory References

  1. Health Canada's Non-prescription Oral Cough, Cold and Flu Labelling Standard
Advertisements

Eligibility and Restrictions for Use

This section outlines the official regulatory restrictions for using Sensibit D NF (Loratadine, Phenylephrine, and Paracetamol).

Contraindicated Populations

Use of this medicine is prohibited for:

  • Individuals with known hypersensitivity (allergy) to any component of the formula (Loratadine, Phenylephrine, Paracetamol, or excipients).
  • Patients currently taking a Monoamine Oxidase Inhibitor (MAOI) or who have taken one within the past two weeks.

Restricted Populations Requiring Consultation

Patients with the following pre-existing conditions or physiological states must consult a healthcare provider before use, as the medicine may be restricted or require special consideration:

  • Cardiovascular disease (especially severe or uncontrolled hypertension and other serious heart conditions).
  • Liver disease (hepatic impairment).
  • Kidney disease (renal impairment).
  • Thyroid disease.
  • Diabetes.
  • Trouble urinating (e.g., due to prostate problems).
  • Pregnancy or lactation (breastfeeding).

Age-Related Eligibility

Regulatory documentation typically indicates the established safe use for adults and children 12 years of age and older. Safety and efficacy in children younger than 12 years are not always established for this specific combination product.

Regulatory Constraints on Purchase

Products containing the decongestant component may be subject to strict behind-the-counter dispensing rules, requiring photo identification and logbook recording in certain jurisdictions due to federal regulations.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Sensibit D NF is defined by the three active components: Acetaminophen, Loratadine, and Phenylephrine Hydrochloride. Regulatory documents specify combinations that are contraindicated or require strict administration constraints due to documented pharmacokinetic and pharmacodynamic interactions.

Contraindicated Combinations and Time Restrictions

Co-administration is strictly prohibited with Monoamine Oxidase Inhibitors (MAOIs). This constitutes a formal contraindication for the Phenylephrine component, requiring a mandatory 14-day washout period after stopping MAOI therapy. Pimozide is also contraindicated due to a pharmacokinetic interaction that increases the plasma concentration of Loratadine.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances Official Description of Outcome
Pharmacokinetic CYP Enzyme Inhibitors (e.g., Ketoconazole, Erythromycin, Cimetidine) Documented to increase the systemic exposure (AUC/Cmax) of Loratadine and its metabolite, Desloratadine.
Pharmacodynamic Antihypertensive Agents (e.g., Beta-blockers) Phenylephrine may formally reduce the therapeutic effectiveness of these medicines.
Pharmacodynamic CNS Depressants Potential for additive impairment of psychomotor performance.

Non-Medicinal Substance Restrictions

Official labeling includes a restriction regarding co-administration with alcohol. This is due to the formally documented risk of severe hepatotoxicity from the Acetaminophen component, especially with chronic consumption.

Advertisements

Mechanism of Action

The mechanism of action for Sensibit D NF involves the pharmacodynamic effects of its two active components that modulate distinct physiological pathways.

H1 Receptor Inverse Agonism

Loratadine acts as an inverse agonist at peripheral H1 histamine receptors, inhibiting their constitutive activity. This action effectively decreases the histamine-mediated signaling cascade that typically involves G-protein coupling, thereby reducing the biochemical triggers for inflammation and vascular changes.


alpha-Adrenergic Receptor Agonism

The sympathomimetic amine component constricts vascular smooth muscle, primarily in the nasal mucosa, through direct agonism of alpha-adrenergic receptors. This localized receptor activation induces potent vasoconstriction and reduces blood flow to the affected tissue.


Integrated Physiological Consequence

The combined actions of H1 inverse agonism and alpha-adrenergic vasoconstriction result in a reduction of tissue hyperemia and associated fluid exudation by minimizing local vascular permeability. This is the mechanistic basis for the reduction of tissue edema formation.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Sensibit D NF

This section outlines the documented instructions for the administration of Sensibit D NF (Loratadine 2.5 mg, Phenylephrine 5 mg, and Paracetamol 500 mg).

Administration Scope Details (Oral Route)
Official Dosing Two tablets every 12 hours.
Frequency Twice daily (every 12 hours).
Preparation No preparation steps (e.g., dilution or reconstitution) are specified for the tablet form.
Maximum Use Do not exceed the recommended dose. Do not use for more than 7 consecutive days without medical supervision.

Age-Group Administration Rules:

  • Adults and Children 12 years and older: The dose is two tablets every 12 hours.
  • Children under 12 years: Not recommended for use in children under this age.
  • Pregnancy/Lactation: Use is not recommended during pregnancy and lactation due to the lack of established safety data for the combination.

Special Procedural Conditions:

Patients must be strictly advised not to consume alcoholic beverages and not to use any other products containing paracetamol (acetaminophen) concurrently with this medication to avoid exceeding the maximum safe daily limit for paracetamol.


The established protocol directs the use of two tablets taken orally, with the dose repeated every twelve hours. The administration is governed by explicit limitations on duration and mandatory warnings against co-administration with other paracetamol products.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sensibit D NF

This section summarizes the official clinical research that authoritative bodies reference when reviewing the research for multi-component fixed-dose combination (FDC) medicines. This overview is based strictly on the publicly documented research landscape and focuses on the types of studies conducted, the populations included, and the key outcomes that were monitored.


Evidence for Use in Common Cold and Flu-Like Symptoms

The research base for this combination product includes short-term Randomized Controlled Trials (RCTs), as well as Systematic Reviews and Meta-Analyses. This research examined the combination's use in adult patients experiencing conditions characterized by fluctuating or episodic manifestations like the common cold or flu-like syndrome.

Studies primarily explored adult populations and tracked measurements of overall symptom severity using tools like the Total Symptom Score (TSS). Researchers also monitored individual patient-reported outcomes describing perceived discomfort related to pain, elevated temperature, and nasal symptoms. Research describes short-term changes that were observed in the studied populations over the typical 3-to-5-day follow-up periods.

Evidence for Managing Concurrent Allergic Rhinitis, Pain, and Fever

The evidence for this indication involves regulatory analyses that synthesize data from established RCTs for the individual components and combination trials. The research was applied in studies examining patient-reported experiences when allergic symptoms coincide with systemic discomforts, such as pain and fever.

Studies explored how the combination product was evaluated in patients who presented with this acute co-occurrence of symptoms. Trials monitored scores related to both allergic rhinitis manifestations and outcomes related to systemic or functional imbalance (fever and pain intensity). The findings describe patterns observed in the studies related to the scores measured across these multiple domains.


Research Gaps and Areas of Scientific Uncertainty

Clinical trials for this combination are almost exclusively focused on acute conditions; therefore, long-term effects are not fully established and limited information is available for durability of effect beyond the acute phase. The research provides context but not individual predictions.

Data for certain groups remain insufficient. Limited data are available for younger patients or pediatric populations, and subgroup findings are uncertain for older adults or those with underlying chronic health conditions, as the results apply only to the populations studied in the primary trials.

The most noted scientific uncertainty relates to the sympathomimetic component. Evidence is limited, and certainty remains low regarding the evidence of the oral Phenylephrine sympathomimetic component in trials. This finding indicates that for the nasal congestion component, the research may show measured score changes that are not clearly distinguishable from placebo.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Sensibit D NF (FAQ)

Q: What is the main difference between Sensibit D NF and regular Sensibit?

A: Official documents indicate that Sensibit D NF is a fixed-dose combination containing three active ingredients: the antihistamine Loratadine, the pain/fever reducer Acetaminophen, and a decongestant, Phenylephrine. Products often referred to as 'regular Sensibit' typically contain only Loratadine. The 'D NF' formulation is a fixed-dose combination structure intended to address multiple symptoms.


Q: How long does it typically take for Sensibit D NF to start working?

A: According to the pharmacological information available, the antihistamine component, Loratadine, typically reaches its peak effect within 1 to 2 hours after being taken. The combination product is formulated to begin providing symptomatic relief as its components are absorbed.


Q: Is it safe to drive or operate machinery after taking Sensibit D NF?

A: Regulatory labeling advises that this medication may impair thinking or reactions in some individuals. Official documents caution that patients may need to be careful when performing activities that require full alertness, such as driving or operating heavy machinery. Patients can determine their own response to the medicine before engaging in such tasks.


Q: How long does one dose of Sensibit D NF last?

A: The official administration guidelines for Sensibit D NF specify that the standard dose is taken every 12 hours. This dosing interval indicates the recommended time between doses for the medicine.


Q: Is it possible to become dependent on Sensibit D NF for relief?

A: Official regulatory warnings for the decongestant component, Phenylephrine, primarily focus on cardiovascular effects and the need for caution with high dosages. Statements concerning the potential for physical dependence or habit formation are not typically included in the core regulatory documents for this combination product.


Q: What should I do if I miss a dose of Sensibit D NF?

A: General regulatory guidance for similar combination products describes protocols for a missed dose, such as taking it as soon as it is remembered. If it is near the time of the next scheduled dose, the protocol typically involves skipping the missed dose to avoid consuming extra medicine.


Q: Can Sensibit D NF affect the results of allergy skin tests?

A: Official guidance associated with the antihistamine component states that the medicine must be stopped for a specified period, often around seven days, prior to allergy skin testing to prevent interference with results.


Q: Is Sensibit D NF available over the counter, or is a prescription required?

A: This product is classified as a non-prescription (Over-the-Counter) medication because its active ingredients are covered by regulatory OTC drug monographs. However, due to the decongestant component, it may be subject to behind-the-counter dispensing rules in certain regions, requiring proper identification for purchase.


Q: Why is this medication sometimes restricted in purchase quantity?

A: Regulatory constraints, such as limits on purchase quantity and logbook recording, are often mandated by law due to the decongestant component's status. These rules are put in place to prevent the misuse of similar substances, particularly Pseudoephedrine, in the illegal manufacture of illicit drugs.


Q: Why do official documents mention 'pseudoephedrine' for this drug?

A: Official documents for Sensibit D NF list Phenylephrine as the decongestant, not Pseudoephedrine. However, regulatory bodies frequently discuss Phenylephrine and Pseudoephedrine together due to the historical change where Phenylephrine was substituted for Pseudoephedrine following regulatory changes.


Q: Are there different strengths or versions of Sensibit D NF available?

A: Regulatory submissions list the exact component strengths for the approved formulation, which is defined as a single, fixed-dose combination (FDC). While different strengths of the individual active components exist as separate products, the Sensibit D NF combination is typically approved in one specific strength.


Q: Does Sensibit D NF affect blood sugar levels?

A: Official warnings indicate that the decongestant component (Phenylephrine) may potentially interfere with blood glucose control. Patients with pre-existing diabetes are among the restricted populations who must seek consultation before using the medicine.


Q: Does Sensibit D NF contain lactose or gluten?

A: The official product labeling contains the complete list of ingredients, which includes the excipients (inactive substances) used in the formulation. The official labeling can be reviewed to confirm the presence or absence of specific inactive ingredients like lactose or gluten.


Q: Is the drug approved for use in all countries, or just specific regions?

A: The drug is documented in regulatory bodies specific to certain regions, such as COFEPRIS (Mexico) and Health Canada. Regulatory approval for any medicine is granted on a country-by-country or regional basis and is not automatically granted for global use.


Q: Is there a version of this drug without the decongestant?

A: While the Sensibit D NF fixed-dose combination contains a decongestant, a version that includes only the antihistamine and analgesic components (Loratadine and Acetaminophen) is commonly available as an alternative product.


Q: Does taking Sensibit D NF make you feel jittery or anxious?

A: Official regulatory documents list side effects such as feeling restless or irritable as common side effects. The decongestant component, in particular, may contribute to feelings of anxiety or confusion in certain patients, as described in the official safety profile.


Q: Are there any specific foods or drinks to avoid while taking Sensibit D NF?

A: Official labeling strictly restricts combining this medicine with alcohol. This is an important safety constraint due to the risk of severe liver toxicity associated with the Acetaminophen component. No common food restrictions are uniformly documented in the regulatory warnings.

Advertisements

How should Sensibit D NF be stored and disposed of?

Storage and Disposal Requirements

Sensibit D NF (Acetaminophen, Loratadine, Phenylephrine HCl) must be stored according to strict regulatory conditions to ensure stability. The product is required to be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from light and kept from freezing or moisture. All tablets must be stored in their original, tightly closed container and kept out of the sight and reach of children.

For disposal, official instructions prioritize using an authorized drug take-back option. If take-back is unavailable, the expired or unused medicine should be mixed with an undesirable substance (such as dirt or used coffee grounds) and sealed in a container before being placed in the household trash, as specified by regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sensibit D NF found in:

A-Z Index: